Full-Time
Develops therapies for rare diseases
$207k - $289.9k/yr
Senior, Expert
Bridgewater Township, NJ, USA
In Person
May require some travel.
Insmed develops therapies for patients with serious and rare diseases. The company focuses on unmet medical needs and has a pipeline of clinical trials and approved treatments. Its products work by targeting specific conditions that currently lack effective treatments, and Insmed generates revenue through the sale of these therapies. What sets Insmed apart from competitors is its strong commitment to patient care and its global presence, with offices in the US, Europe, and Japan. The goal of Insmed is to address diverse healthcare challenges and improve the lives of patients with rare diseases.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Richmond, Virginia
Founded
1988
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Health Insurance
Paid Vacation
Employee Stock Purchase Plan
Company Equity
Insmed raised $750 million after positive Phase IIb data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension, boosting its stock by 29% to $90.93. The company sold 7.81 million shares at $96 each in a follow-on public offering. This comes 13 months after a previous offering of 12.62 million shares at $51.50.
The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $750 million.
Insmed –Insmed Inc., a global biopharmaceutical company, Tuesday announced positive topline results from its Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH).The results of the double-blind, placebo-controlled study demonstrated the durability of TPIP’s therapeutic effect as a once-daily therapy based on efficacy being evaluated about 24 hours after therapy was administered.Based on these results, Insmed will engage with the Food and Drug Administration regarding the Phase 3 trial design for pulmonary arterial hypertension. Insmed plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial in patients with PAH in early 2026.Pulmonary arterial hypertension is a progressive, rare disease in which the blood vessels in the lungs narrow or become obstructed, leading to high blood pressure in the pulmonary arteries. The most common symptoms include shortness of breath, chest pain, dizziness or fainting, fatigue, and weakness. It is estimated that about 35,000 patients in the U.S. have been diagnosed with the disease. Untreated, PAH can be debilitating and often fatal.“The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy,” said Gene Sullivan, chief product strategy officer of Insmed.The study was conducted at 44 sites globally; 102 patients were randomized to receive either TPIP or placebo for 16 weeks
BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT.
Proficio Capital Partners LLC invests $1.86 million in Insmed Incorporated (NASDAQ:INSM).